Monitoring of NC 50/90 in blood samples of breast cancer patients
US5593847A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Dec 20, 1993 |
| Grant date | Jan 14, 1997 |
| Priority date | — |
| Expiry date | Dec 20, 2013 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S436/813
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
A method for aiding in the diagnosis of, and monitoring the progression of, breast cancer in a patient by measuring the amount of NCA 50/90 in a blood sample, e.g. serum sample, obtained from the patient. Measurement in a single sample of an amount of NCA 50/90 significantly higher than the mean amount of NCA 50/90 in the normal population is an indication of breast cancer in the patient. The progression of breast cancer can also be monitored by performing a series of specific immunoassays over time to determine changes in the level of NCA 50/90 in blood samples. Increases in blood NCA 50/90 levels over time are indicative of a deteriorating condition whereas decreasing levels of blood NCA 50/90 over time indicate an improving condition.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.